• Profile
Close

A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas

Pediatric Blood & Cancer Nov 07, 2017

Kilburn LB, et al. - The intent of the authors was to analyze the progression-free survival (PFS) in children with newly diagnosed diffuse intrinsic pontine gliomas (DIPG), who were given oral capecitabine rapidly disintegrating tablets concurrently with radiation therapy (RT). It was deduced that capecitabine did not improve the outcome for children with newly diagnosed DIPG.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay